Microorganisms engineered for muconate production

Abstract

Disclosed herein are the genetically modified Pseudomonas with improved tolerance to hydroxycinnamic acids.

Description

SUMMARY

In an aspect disclosed herein is a genetically modified Pseudomonas comprising a mutation of a gene encoding a cell membrane protein wherein the modification improves tolerance to hydroxycinnamic acid relative to the non-genetically modified Pseudomonas. A method for lignin valorization, the method comprising: converting a hydroxycinnamic acid to muconate utilizing a genetically modified Pseudomonas comprising: a modification of a gene encoding a cell membrane protein; wherein the modification increases the uptake of the hydroxycinnamic acid relative to the uptake of a non-genetically modified Pseudomonas.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted via EFS-web and is hereby incorporated by reference in its entirety. The ASCII copy as filed herewith was created on 24 Feb. 2021. The ASCII copy as filed herewith is named NREL 20-48_ST25.txt, is 9 kilobytes in size and is submitted with the instant application.

BRIEF DESCRIPTION OF DRAWINGS

Some embodiments are illustrated in referenced figures of the drawings. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than limiting.

FIG. 1 depicts fitness trajectories of the ALE experiment on glucose. Depicted are the fitness trajectories of evolved P. puitda (growth rate, h⁻¹) in a static concentration of 10 g/L glucose over the cumulative cell divisions (CCD). Each of four biological replicates of the glucose ALE experiment are plotted.

FIGS. 2A through 2I depict representative trajectories of population fitness and aromatic acid concentrations over the course of TALE experiments. Depicted are the fitness trajectories of evolved P. putida (growth rate, h⁻¹) as a function of the increasing hydroxycinnamic acid concentration over the course of the TALE experiments as a function of the cumulative cells division (CCD) for (FIGS. 2A, 2B, and 2C) pCA TALEs #1, #3, #5, #7, #9, and #11, (FIGS. 2D, 2E, and 2F) FA TALEs #13, #15, #17, #19, #21, and #23, and (FIGS. 2G, 2H, and 2I) pCA+FA TALEs (equivalent mass pCA and FA, the sum is plotted) #25, #27, #29, #31, #33, and #35. The concentration of each aromatic acid is shown as an orange line and growth rate is shown as a blue diamond.

FIGS. 3A, 3B, and 3C depict experimental and growth parameters for p-coumarate (pCA) tolerance adaptive laboratory evolution (TALE), ferulate (FA) TALE, equal mass mixture pCA and FA (pCA+FA) TALE, and glucose adaptive laboratory evolution (ALE). (FIG. 3A) Duration of each experiment in number of passages and cumulative cell divisions (CCD). (FIG. 3B) Substrate concentration at the start (C_initial) and end (C_final) of each experiment, and the fold-change increase from t₀ to t_f. For the pCA+FA conditions, substrate concentration is presented as a sum where each individual compound is present in a 1:1 mass ratio. (FIG. 3C) Bacterial growth rate at the start (μ_initial) and end (μ_final) of each experiment. Error bars represent the standard deviation of biological replicates (n=6 for pCA, FA, and pCA+FA, n=3 for glucose). TALE: Tolerance adaptive laboratory evolution; ALE: adaptive laboratory evolution.

FIGS. 4A, 4B, 4C, and 4D depict population screen of wild-type P. putida and evolved populations from p-coumararte (pCA TALE #3 and TALE #9), ferulate (FA TALE #13 and TALE #19), equal mass mixture of p-coumarate and ferulate (pCA+FA TALE #31 and TALE #37) TALES and glucose (Glucose ALE #37 and ALE #38) taken at the endpoint. Growth rates from test tube cultivations in M9 minimal media supplemented with (FIG. 4A) 10 g/L pCA or 20 g/L pCA, (FIG. 4B) 10 g/L FA or 30 g/L FA, (FIG. 4C) 10 g/LpCA+FA (5 g/L each) or 20 g/L pCA+FA (10 g/L each), and (FIG. 4D) 10 g/L glucose. Dashed grey lines are provided to aid in the visual comparison of mutant values to wild-type values. Error bars represent the absolute difference between biological duplicates.

FIG. 5 depicts the total number and types of unique mutations identified in pCA TALE, FA TALE, pCA+FA TALE (equal mass mixture), or glucose ALE. Abbreviations: pCA, p-coumaric acid; FA, ferulic acid; SNP, single nucleotide polymorphism.

FIG. 6 depicts putida from pCA, FA, and pCA+FA TALEs or glucose ALE. Genes/genetic loci are listed on the left-hand side. Line width is proportional to the number of unique occurrences in which a given gene or genetic region was mutated. See Table 1 for another depiction of converged mutations.

FIGS. 7A, 7B, 7C, and 7D depict Growth characteristics of P. putida wild-type PP_3350 mutants on pCA and/or FA as the sole carbon source. (FIG. 7A) Overview of mutations in CJ782 and TALE endpoint populations tested here. Mutations are depicted for those which are fully fixed in a population; details on each strain can be found in Table 2. Deletions are denoted with an Δ; single nucleotide polymorphisms (SNPs) in ttgB and sucA ORFs are denoted with the AA1:position:AA2 notation; SNPs in the intergenic region between PP_5245 and kefB-III are denoted with nucleotide→nucleotide notation. Growth rate and lag phase of wild-type P. putida (WT), P. putida ΔPP_3350 (CJ782), and three TALE endpoint populations (TALE #7, #23, and #25) in (a) 10 g/L or 20 g/L pCA, (FIG. 7B) 10 g/L or 30 g/L FA, (FIG. 7C) 5 g/L pCA plus 5 g/L FA (10 g/L total) or 10 g/L pCA plus 10 g/L FA (20 g/L total), and (FIG. 7D) 20 g/L pCA+FA (10 g/L of each compound). Cells were cultivated in duplicate in M9 minimal media supplemented with the specified amount of aromatic compound. Error bars represent the absolute difference of two biological replicates.

DETAILED DESCRIPTION

The embodiments described herein should not necessarily be construed as limited to addressing any of the particular problems or deficiencies discussed herein. References in the specification to “one embodiment”, “an embodiment”, “an example embodiment”, “some embodiments”, etc., indicate that the embodiment described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it is submitted that it is within the knowledge of one skilled in the art to affect such feature, structure, or characteristic in connection with other embodiments whether or not explicitly described.

As used herein the term “substantially” is used to indicate that exact values are not necessarily attainable. By way of example, one of ordinary skill in the art will understand that in some chemical reactions 100% conversion of a reactant is possible, yet unlikely. Most of a reactant may be converted to a product and conversion of the reactant may asymptotically approach 100% conversion. So, although from a practical perspective 100% of the reactant is converted, from a technical perspective, a small and sometimes difficult to define amount remains. For this example of a chemical reactant, that amount may be relatively easily defined by the detection limits of the instrument used to test for it. However, in many cases, this amount may not be easily defined, hence the use of the term “substantially”. In some embodiments of the present invention, the term “substantially” is defined as approaching a specific numeric value or target to within 20%, 15%, 10%, 5%, or within 1% of the value or target. In further embodiments of the present invention, the term “substantially” is defined as approaching a specific numeric value or target to within 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the value or target.

As used herein, the term “about” is used to indicate that exact values are not necessarily attainable. Therefore, the term “about” is used to indicate this uncertainty limit. In some embodiments of the present invention, the term “about” is used to indicate an uncertainty limit of less than or equal to ±20%, ±15%, ±10%, ±5%, or ±1% of a specific numeric value or target. In some embodiments of the present invention, the term “about” is used to indicate an uncertainty limit of less than or equal to ±1%, ±0.9%, ±0.8%, ±0.7%, ±0.6%, ±0.5%, ±0.4%, ±0.3%, ±0.2%, or ±0.1% of a specific numeric value or target.

sdfsdf A “vector” or “recombinant vector” is a nucleic acid molecule that is used as a tool for manipulating a nucleic acid sequence of choice or for introducing such a nucleic acid sequence into a host cell. A vector may be suitable for use in cloning, sequencing, or otherwise manipulating one or more nucleic acid sequences of choice, such as by expressing or delivering the nucleic acid sequence(s) of choice into a host cell to form a recombinant cell. Such a vector typically contains heterologous nucleic acid sequences not naturally found adjacent to a nucleic acid sequence of choice, although the vector can also contain regulatory nucleic acid sequences (e.g., promoters, untranslated regions) that are naturally found adjacent to the nucleic acid sequences of choice or that are useful for expression of the nucleic acid molecules.

A vector can be either RNA or DNA, either prokaryotic or eukaryotic, and typically is a plasmid. The vector can be maintained as an extrachromosomal element (e.g., a plasmid) or it can be integrated into the chromosome of a recombinant host cell. The entire vector can remain in place within a host cell, or under certain conditions, the plasmid DNA can be deleted, leaving behind the nucleic acid molecule of choice. An integrated nucleic acid molecule can be under chromosomal promoter control, under native or plasmid promoter control, or under a combination of several promoter controls. Single or multiple copies of the nucleic acid molecule can be integrated into the chromosome. A recombinant vector can contain at least one selectable marker.

The term “expression vector” refers to a recombinant vector that is capable of directing the expression of a nucleic acid sequence that has been cloned into it after insertion into a host cell or other (e.g., cell-free) expression system. A nucleic acid sequence is “expressed” when it is transcribed to yield an mRNA sequence. In most cases, this transcript will be translated to yield an amino acid sequence. The cloned gene is usually placed under the control of (i.e., operably linked to) an expression control sequence. The phrase “operatively linked” refers to linking a nucleic acid molecule to an expression control sequence in a manner such that the molecule can be expressed when introduced (i.e., transformed, transduced, transfected, conjugated and/or conduced) into a host cell.

Vectors and expression vectors may contain one or more regulatory sequences or expression control sequences. Regulatory sequences broadly encompass expression control sequences (e.g., transcription control sequences or translation control sequences), as well as sequences that allow for vector replication in a host cell. Transcription control sequences are sequences that control the initiation, elongation, and/or termination of transcription. Suitable regulatory sequences include any sequence that can function in a host cell or organism into which the recombinant nucleic acid molecule is to be introduced, including those that control transcription initiation, such as promoter, enhancer, terminator, operator, and/or repressor sequences. Additional regulatory sequences include translation regulatory sequences, origins of replication, and other regulatory sequences that are compatible with the recombinant cell. The expression vectors may contain elements that allow for constitutive expression or inducible expression of the protein or proteins of interest. Numerous inducible and constitutive expression systems are known in the art.

Typically, an expression vector includes at least one nucleic acid molecule of interest operatively linked to one or more expression control sequences (e.g., transcription control sequences or translation control sequences). In one aspect, an expression vector may comprise a nucleic acid encoding a recombinant polypeptide, as described herein, operably linked to at least one regulatory sequence. It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of polypeptide to be expressed.

Expression and recombinant vectors may contain a selectable marker, a gene encoding a protein necessary for survival or growth of a host cell transformed with the vector. The presence of this gene allows growth of only those host cells that express the vector when grown in the appropriate selective media. Typical selection genes encode proteins that confer resistance to antibiotics or other toxic substances, complement auxotrophic deficiencies, or supply critical nutrients not available from a particular media. Markers may be an inducible or non-inducible gene and will generally allow for positive selection. Non-limiting examples of selectable markers include the ampicillin resistance marker (i.e., beta-lactamase), tetracycline resistance marker, neomycin/kanamycin resistance marker (i.e., neomycin phosphotransferase), dihydrofolate reductase, glutamine synthetase, and the like. The choice of the proper selectable marker will depend on the host cell, and appropriate markers for different hosts as understood by those of skill in the art.

Suitable expression vectors may include (or may be derived from) plasmid vectors that are well known in the art, such as those commonly available from commercial sources. Vectors can contain one or more replication and inheritance systems for cloning or expression, one or more markers for selection in the host, and one or more expression cassettes. The inserted coding sequences can be synthesized by standard methods, isolated from natural sources, or prepared as hybrids. Ligation of the coding sequences to transcriptional regulatory elements or to other amino acid encoding sequences can be carried out using established methods. A large number of vectors, including bacterial, yeast, and mammalian vectors, have been described for replication and/or expression in various host cells or cell-free systems, and may be used with the sequences described herein for simple cloning or protein expression.

SEQ ID NOs: 1-2 provide nucleic acid and amino acid sequences for exemplary enzymes for use in the disclosed methods. “Nucleic acid” or “polynucleotide” as used herein refers to purine- and pyrimidine-containing polymers of any length, either polyribonucleotides or polydeoxyribonucleotide or mixed polyribo-polydeoxyribonucleotides. This includes single- and double-stranded molecules (i.e., DNA-DNA, DNA-RNA and RNA-RNA hybrids) as well as “protein nucleic acids” (PNA) formed by conjugating bases to an amino acid backbone. This also includes nucleic acids containing modified bases.

Nucleic acids referred to herein as “isolated” are nucleic acids that have been removed from their natural milieu or separated away from the nucleic acids of the genomic DNA or cellular RNA of their source of origin (e.g., as it exists in cells or in a mixture of nucleic acids such as a library) and may have undergone further processing. Isolated nucleic acids include nucleic acids obtained by methods described herein, similar methods or other suitable methods, including essentially pure nucleic acids, nucleic acids produced by chemical synthesis, by combinations of biological and chemical methods, and recombinant nucleic acids that are isolated.

Nucleic acids referred to herein as “recombinant” are nucleic acids which have been produced by recombinant DNA methodology, including those nucleic acids that are generated by procedures that rely upon a method of artificial replication, such as the polymerase chain reaction (PCR) and/or cloning or assembling into a vector using restriction enzymes. Recombinant nucleic acids also include those that result from recombination events that occur through the natural mechanisms of cells but are selected for after the introduction to the cells of nucleic acids designed to allow or make probable a desired recombination event. Portions of isolated nucleic acids that code for polypeptides having a certain function can be identified and isolated by, for example, the method disclosed in U.S. Pat. No. 4,952,501.

A nucleic acid molecule or polynucleotide can include a naturally occurring nucleic acid molecule that has been isolated from its natural source or produced using recombinant DNA technology (e.g., polymerase chain reaction (PCR) amplification, cloning) or chemical synthesis. Isolated nucleic acid molecules can include, for example, genes, natural allelic variants of genes, coding regions or portions thereof, and coding and/or regulatory regions modified by nucleotide insertions, deletions, substitutions, and/or inversions in a manner such that the modifications do not substantially interfere with the nucleic acid molecule's ability to encode a polypeptide or to form stable hybrids under stringent conditions with natural gene isolates. An isolated nucleic acid molecule can include degeneracies. As used herein, nucleotide degeneracy refers to the phenomenon that one amino acid can be encoded by different nucleotide codons. Thus, the nucleic acid sequence of a nucleic acid molecule that encodes a protein or polypeptide can vary due to degeneracies.

Unless so specified, a nucleic acid molecule is not required to encode a protein having enzyme activity. A nucleic acid molecule can encode a truncated, mutated or inactive protein, for example. In addition, nucleic acid molecules may also be useful as probes and primers for the identification, isolation and/or purification of other nucleic acid molecules, independent of a protein-encoding function.

Suitable nucleic acids include fragments or variants that encode a functional enzyme. For example, a fragment can comprise the minimum nucleotides required to encode a functional enzyme. Nucleic acid variants include nucleic acids with one or more nucleotide additions, deletions, substitutions, including transitions and transversions, insertion, or modifications (e.g., via RNA or DNA analogs). Alterations may occur at the 5′ or 3′ terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

In certain embodiments, a nucleic acid may be identical to a sequence represented herein. In other embodiments, the nucleic acids may be at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequence represented herein, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a sequences represented herein. Sequence identity calculations can be performed using computer programs, hybridization methods, or calculations. Exemplary computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package, BLASTN, BLASTX, TBLASTX, and FASTA. The BLAST programs are publicly available from NCBI and other sources. For example, nucleotide sequence identity can be determined by comparing query sequences to sequences in publicly available sequence databases (NCBI) using the BLASTN2 algorithm.

Nucleic acids may be derived from a variety of sources including DNA, cDNA, synthetic DNA, synthetic RNA, or combinations thereof. Such sequences may comprise genomic DNA, which may or may not include naturally occurring introns. Moreover, such genomic DNA may be obtained in association with promoter regions or poly (A) sequences. The sequences, genomic DNA, or cDNA may be obtained in any of several ways. Genomic DNA can be extracted and purified from suitable cells by means well known in the art. Alternatively, mRNA can be isolated from a cell and used to produce cDNA by reverse transcription or other means.

Also disclosed herein are recombinant vectors, including expression vectors, containing nucleic acids encoding enzymes. A “recombinant vector” is a nucleic acid molecule that is used as a tool for manipulating a nucleic acid sequence of choice or for introducing such a nucleic acid sequence into a host cell. A recombinant vector may be suitable for use in cloning, assembling, sequencing, or otherwise manipulating the nucleic acid sequence of choice, such as by expressing or delivering the nucleic acid sequence of choice into a host cell to form a recombinant cell. Such a vector typically contains heterologous nucleic acid sequences not naturally found adjacent to a nucleic acid sequence of choice, although the vector can also contain regulatory nucleic acid sequences (e.g., promoters, untranslated regions) that are naturally found adjacent to the nucleic acid sequences of choice or that are useful for expression of the nucleic acid molecules.

The nucleic acids described herein may be used in methods for production of enzymes and enzyme cocktails through incorporation into cells, tissues, or organisms. In some embodiments, a nucleic acid may be incorporated into a vector for expression in suitable host cells. The vector may then be introduced into one or more host cells by any method known in the art. One method to produce an encoded protein includes transforming a host cell with one or more recombinant nucleic acids (such as expression vectors) to form a recombinant cell. The term “transformation” is generally used herein to refer to any method by which an exogenous nucleic acid molecule (i.e., a recombinant nucleic acid molecule) can be inserted into a cell but can be used interchangeably with the term “transfection.”

Non-limiting examples of suitable host cells include cells from microorganisms such as bacteria, yeast, fungi, and filamentous fungi. Exemplary microorganisms include, but are not limited to, bacteria such as E. coli; bacteria from the genera Pseudomonas (e.g., P. putida or P. fluorescens), Bacillus (e.g., B. subtilis, B. megaterium or B. brevis), Caulobacter (e.g., C. crescentus), Lactoccocus (e.g., L. lactis), Streptomyces (e.g., S. coelicolor), Streptococcus (e.g., S. lividans), and Corynybacterium (e.g., C. glutamicum); fungi from the genera Trichoderma (e.g., T. reesei, T. viride, T. koningii, or T. harzianum), Penicillium (e.g., P. funiculosum), Humicola (e.g., H. insolens), Chrysosporium (e.g., C. lucknowense), Gliocladium, Aspergillus (e.g., A. niger, A. nidulans, A. awamori, or A. aculeatus), Fusarium, Neurospora, Hypocrea (e.g., H. jecorina), and Emericella; yeasts from the genera Saccharomyces (e.g., S. cerevisiae), Pichia (e.g., P. pastoris), or Kluyveromyces (e.g., K. lactis). Cells from plants such as Arabidopsis, barley, citrus, cotton, maize, poplar, rice, soybean, sugarcane, wheat, switch grass, alfalfa, miscanthus, and trees such as hardwoods and softwoods are also contemplated herein as host cells.

Host cells can be transformed, transfected, or infected as appropriate by any suitable method including electroporation, calcium chloride-, lithium chloride-, lithium acetate/polyene glycol-, calcium phosphate-, DEAE-dextran-, liposome-mediated DNA uptake, spheroplasting, injection, microinjection, microprojectile bombardment, phage infection, viral infection, or other established methods. Alternatively, vectors containing the nucleic acids of interest can be transcribed in vitro, and the resulting RNA introduced into the host cell by well-known methods, for example, by injection. Exemplary embodiments include a host cell or population of cells expressing one or more nucleic acid molecules or expression vectors described herein (for example, a genetically modified microorganism). The cells into which nucleic acids have been introduced as described above also include the progeny of such cells.

Vectors may be introduced into host cells such as those from bacteria or fungi by direct transformation, in which DNA is mixed with the cells and taken up without any additional manipulation, by conjugation, electroporation, or other means known in the art. Expression vectors may be expressed by bacteria or fungi or other host cells episomally or the gene of interest may be inserted into the chromosome of the host cell to produce cells that stably express the gene with or without the need for selective pressure. For example, expression cassettes may be targeted to neutral chromosomal sites by recombination.

Host cells carrying an expression vector (i.e., transformants or clones) may be selected using markers depending on the mode of the vector construction. The marker may be on the same or a different DNA molecule. In prokaryotic hosts, the transformant may be selected, for example, by resistance to ampicillin, tetracycline or other antibiotics. Production of a particular product based on temperature sensitivity may also serve as an appropriate marker.

Host cells may be cultured in an appropriate fermentation medium. An appropriate, or effective, fermentation medium refers to any medium in which a host cell, including a genetically modified microorganism, when cultured, is capable of growing or expressing the polypeptides described herein. Such a medium is typically an aqueous medium comprising assimilable carbon, nitrogen and phosphate sources, but can also include appropriate salts, minerals, metals and other nutrients. Microorganisms and other cells can be cultured in conventional fermentation bioreactors and by any fermentation process, including batch, fed-batch, cell recycle, and continuous fermentation. The pH of the fermentation medium is regulated to a pH suitable for growth of the particular organism. Culture media and conditions for various host cells are known in the art. A wide range of media for culturing bacteria or fungi, for example, are available from ATCC.

The nucleic acid molecules described herein encode the proteins with amino acid sequences such as those represented by some of the SEQ ID NOs presented herein. As used herein, the terms “protein” and “polypeptide” are synonymous. “Peptides” are defined as fragments or portions of polypeptides, preferably fragments or portions having at least one functional activity as the complete polypeptide sequence. “Isolated” proteins or polypeptides are proteins or polypeptides purified to a state beyond that in which they exist in cells. In certain embodiments, they may be at least 10% pure; in others, they may be substantially purified to 80% or 90% purity or greater. Isolated proteins or polypeptides include essentially pure proteins or polypeptides, proteins or polypeptides produced by chemical synthesis or by combinations of biological and chemical methods, and recombinant proteins or polypeptides that are isolated. Proteins or polypeptides referred to herein as “recombinant” are proteins or polypeptides produced by the expression of recombinant nucleic acids.

Proteins or polypeptides encoded by nucleic acids as well as functional portions or variants thereof are also described herein. Polypeptide sequences may be identical to the amino acid sequences presented herein or may include up to a certain integer number of amino acid alterations. Such protein or polypeptide variants retain functionality as enzymes, and include mutants differing by the addition, deletion, or substitution of one or more amino acid residues, or modified polypeptides and mutants comprising one or more modified residues. The variant may have one or more conservative changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). Alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence.

In certain embodiments, the polypeptides may be at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequences presented herein and possess enzymatic function. Percent sequence identity can be calculated using computer programs (such as the BLASTP and TBLASTN programs publicly available from NCBI and other sources) or direct sequence comparison. Polypeptide variants can be produced using techniques known in the art including direct modifications to isolated polypeptides, direct synthesis, or modifications to the nucleic acid sequence encoding the polypeptide using, for example, recombinant DNA techniques.

Polypeptides may be retrieved, obtained, or used in “substantially pure” form, a purity that allows for the effective use of the protein in any method described herein or known in the art. For a protein to be most useful in any of the methods described herein or in any method utilizing enzymes of the types described herein, it is most often substantially free of contaminants, other proteins and/or chemicals that might interfere or that would interfere with its use in the method (e.g., that might interfere with enzyme activity), or that at least would be undesirable for inclusion with a protein.

Among other things, the present disclosure relates to engineering microorganisms to have the deletion or a modification of a gene encoding a membrane porin, with one example including the hypothetical protein PP_3350, also called NCBI-Protein NP_745490. As shown herein, these mutations affect the uptake of coumarate and ferulate and their conversion to muconate. In an embodiment, the nucleotide sequence of the gene encoding for hypothetical protein PP_3350 is SEQ ID NO: 1. In an embodiment, the hypothetical protein PP_3350 has an amino acid sequence that is SEQ ID NO: 2. These mutations remove the membrane transfer bottle-neck of substrates (e.g., coumarate and ferulate) into the microorganism allowing faster conversion of the substrates to the desired target molecule (e.g., muconate). As shown herein, one example of a microorganism that has been successfully engineered for enhanced tolerance to high concentrations of coumarate and/or ferulate is Pseudomonas putida. Such modified organisms may dramatically improve large-scale fermentation processes by, for example, allowing higher concentration of substrates, shorter batch times, and increased muconate production rates on a per unit volume basis.

Pseudomonas putida KT2440 is a promising bacterial chassis for the conversion of lignin-derived aromatic compound mixtures to high-value products. Despite the inherent robustness of this strain, improvement to both aromatic catabolic rates and toxicity tolerance of P. putida will be required to achieve industrially relevant bioprocess performance. Described herein is a tolerance adaptive laboratory evolution (TALE) approach using increasing concentrations of the plant-derived, hydroxycinnamic acids, p-coumaric acid (pCA), ferulic acid (FA), and an equal mass mixture of pCA and FA (pCA+FA). After 300-600 passages in each TALE line, evolved P. putida demonstrated increased tolerance to pCA, measured by a 3.3-fold increase in the maximum substrate concentration where growth was enabled, and a 37 hour decrease in lag phase, both at 20 g/L pCA. For FA, substrate utilization and tolerance were both improved; namely, evolved P. putida displayed growth on a 5-fold increase in FA concentration and a 2.4-fold increase in growth rate at 30 g/L FA.

Whole genome resequencing of intermediate and final evolved P. putida populations revealed several non-intuitive genetic targets underlying these aromatic catabolic and toxicity tolerance enhancements. PP_3350 was among the most frequently mutated genes and the beneficial contributions of this mutation was verified in vivo with single gene knockouts. Deletion of PP_3350, encoding a hypothetical protein, fully recapitulated the improved toxicity tolerance to high concentrations of pCA but not the improved growth rate in high concentrations of FA. The work described herein demonstrates improved microbial fitness, in regard to both tolerance and utilization of at least two hydroxycinnamic acids (e.g., coumarate and ferulate) via TALE and presents new targets towards improving P. putida for microbial lignin valorization.

As shown herein, adaptive laboratory evolution (ALE) can be an efficient approach that has proven useful for overcoming substrate toxicity, improving substrate consumption rates, and improving overall strain fitness. In the present disclosure, both the toxicity tolerance and consumption rates of pCA and FA are addressed by utilizing a systematic ALE strategy, tolerance adaptive laboratory evolution (TALE), to generate P. putida strains capable of growing at elevated hydroxycinnamic acid concentrations. Specifically, cells were continuously evolved in independent biological replicates under increasing levels of pCA, FA, and an equal mass ratio of both acids (hereafter referred to as pCA+FA). In addition, ALE was applied evolve P. putida in a static concentration of glucose as a control to enable identification of general adaptive mutations to media components and/or the cultivation conditions as opposed to the aromatic substrate(s) (FIG. 1). Cell populations and single isolates were selected from both TALE and ALE experiments at intermediate and endpoints to identify causal mutations. Endpoint populations were characterized in terms of their growths rates and tolerance levels. Through construction of genetic knockouts in a wild-type P. putida strain, it is shown herein that causal mutations are related to, among other things, PP_3350, encoding a hypothetical protein.

TALE experiments with aromatic compounds were performed by cultivating six independent parallel biological replicates of P. putida in minimal media supplemented with pCA, FA, or an equal mass mixture of pCA and FA (“pCA+FA”) until the growth rate reached 0.15 h⁻¹, at which point the cells were propagated into media with an increased substrate concentration (FIGS. 2A through 2I). Additionally, ALE was performed with P. putida propagated in minimal media supplemented with a static concentration of glucose to identify general adaptation to media components and/or the cultivation conditions in four biological replicates (FIG. 1).

The aromatic TALEs were passaged 69 to 113 times, enabling evolution over 23-35×10¹¹ cumulative cell divisions (CCDs) (FIGS. 3A, 3B, and 3C, FIGS. 2A-2I). By the final passage evolved P. putida cells had developed the capacity to grow in a 3.3-, 5.0-, and 2.5-fold increase in concentration of pCA, FA, and pCA+FA, respectively (FIG. 3B). The final growth rate increased in FA TALEs but not pCA or pCA+FA (FIG. 3C), suggesting that the fitness advantage acquired by P. putida evolved in pCA TALEs was primarily tolerance whereas P. putida evolved in FA TALEs acquired both improved tolerance and utilization capacity. The four independent and parallel glucose ALEs progressed much faster and further than the aromatic TALES, achieving 64×10¹¹ CCDs and a substantial growth rate improvement (FIGS. 3A, 3B, and 3C). The increase in growth rate observed in glucose ALEs occurred within the first third of the experiment and then plateaued (FIG. 1) whereas all of the aromatic TALEs displayed oscillatory growth rate increases/decreases (FIGS. 2A through 2I), indicating that continual adaptation was occurring in dynamic TALEs but not in static ALEs.

Next, population screens were performed to determine if the growth rate increase observed in TALE experiments could be recapitulated in the endpoint populations. Two endpoint populations were selected per TALE, cultivated in test tubes alongside the parent wild-type P. putida, and the growth rates were compared to assess catabolic capacity on the different substrates, independently if the strains were or not evolved in that specific substrate FIGS. 4A, 4B, 4C, and 4D). Growth rate improvements on pCA were modest (FIG. 4A), which is agreement with the TALE measurements (FIG. 3C). Interestingly, FA TALEs were more successful at improving pCA catabolic capacity than pCA TALEs (FIG. 4a. Dramatic growth rate improvements were observed on FA from all evolved populations except those on glucose (FIG. 4B). However, glucose-evolved strains performed better than wild-type on pCA+FA (FIG. 4C) and most of the evolved populations performed better than wild-type on glucose (FIG. 4D). Together these data suggest that mutations acquired by evolved populations cause both general adaptation to the cultivation conditions as well as increased FA and pCA catabolic capacity.

To identify mutations which may contribute to the improved phenotype in evolved populations, whole genome resequencing was performed on three isolates and the endpoint population from intermediate and endpoint flasks for each TALE and ALE experiment. Strain-specific mutations and poor reads were filtered. In total, 62, 139, 76, and 23 mutations were identified in clonal isolates or populations from pCA TALE, FA TALE, pCA+FA TALE, and glucose ALE experiments, respectively. In each TALE and ALE experiment, over 70% of the mutations were single nucleotide polymorphisms (SNPs) with insertion and deletion prevalence varying by experiment (FIG. 5).

Converged mutations were identified by comparing all clonal and population samples and selecting genes which presented a mutation in >2 independent TALE or ALE experiments, either replicates on the same carbon source or in a different carbon source. Several genes were mutated in more than one of the aromatic TALEs but not the glucose ALE, including sucA, rho, PP_3350, ttgB, accD, and the intergenic region between PP_5245 and kefB-III (FIG. 6, Table 1). Many of the converged mutations from glucose ALEs were shared with at least one of the aromatic TALEs (FIG. 6, Table 1) implying that these adaptations are related to the cultivation conditions rather than the carbon source.

TABLE 1
Converged mutations identified in P. putida from pCA, FA, and pCA+FA TALEs or
glucose ALE.
Gene/	Mutation type†		Experiment(s) in which
Region	(unique counts)	Gene annotation(s)‡	mutations were identified¥
gacS	SNP (7), DEL (3)	sensor protein GacS	pCA, FA, pCA + FA, Glucose
oprB-II	SNP (2), DEL (1)	carbohydrate-selective porin	pCA + FA, Glucose
uvrY	SNP (6), INS (1)	BarA/UvrY two-component	pCA, FA, pCA + FA, Glucose
		system response regulator
sucA	SNP (7)	2-oxoglutarate dehydrogenase	pCA, FA, pCA + FA
		subunit E1
rho	SNP (10)	transcription termination factor Rho	pCA, FA, pCA + FA
PP_3350	SNP (6), DEL (12),	hypothetical protein	pCA, FA, pCA + FA
	INS/DUP (3), INS (1)
ttgB	SNP (6)	efflux pump membrane protein TtgB	pCA, pCA + FA
accD	SNP (3)	acetyl-CoA carboxylase	pCA, FA, pCA + FA
		carboxyltransferase subunit beta
PP_5245,	SNP (2)	AraC family transcriptional	pCA, FA, pCA + FA
kefB-III		regulator/glutathione-regulated
		potassium/H+ antiporter
fleQ	SNP (6), DEL (1)	transcriptional regulator FleQ	FA, pCA + FA, Glucose
accA	SNP (2)	acetyl-CoA carboxylase	pCA
		carboxyltransferase subunit alpha
dnak	SNP (2)	chaperone protein Dnak	FA
wbpL	SNP (1), INS (2)	glycosyl transferase WbpL	pCA
PP_1060,	SNP (2)	glutamate synthase large subunit/ATP-	PCA
PP_1061		dependent DNA helicase
rpoN	INS (1), DEL (1)	RNA polymerase sigma-54 factor	pCA + FA
sdhA	SNP (1)	succinate dehydrogenase flavoprotein	pCA + FA
		subunit
oxyR	SNP (1),	oxidative and nitrosative stress	Glucose
	INS/DUP (1)	transcriptional dual regulator
fliR	DUP (1)	flagellar biosynthetic protein FliR	Glucose
†Mutation type abbreviations: SNP, single nucleotide polymorphism; INS, insertion; DEL, deletion; DUP: duplication.
‡Annotations assigned from NCBI Reference Genome NC_002947.X
¥Experiment abbreviations: pCA, TALE in p-coumaric acid; FA, TALE in ferulic acid; pCA + FA, TALE in equimass mixture of p-coumaric acid and ferulic acid; Glucose, ALE in glucose.

Next, individual mutations that underlie the improved phenotypes were identified. One of the most frequently mutated genes in pCA, FA, and pCA+FA TALEs was PP_3350, encoding a hypothetical protein (Table 1,). PP_3350 was mutated extensively with SNPs, insertions, and deletions in pCA, FA, and pCA+FA TALEs. Accordingly, it was hypothesized that deletion of PP_3350 would improve growth in pCA and/or FA. To test this hypothesis a single-gene deletion was constructed in wild-type P. putida of PP_3350 (strain CJ782) and growth was examined alongside endpoint populations which harbored the mutation in the corresponding gene.

The effect of PP_3350 deletions on growth on hydroxycinnamic acids was evaluated. PP_3350 is a hypothetical protein which harbors an 18 stranded ß-barrel pore domain with homology to porins involved in alginate export. Endpoint populations from pCA TALE #7, FA TALE #23, and pCA+FA TALE #25 were selected for comparison with wild-type and CJ782 as they each harbor PP_3350 deletions of varying length in addition to other mutations (FIGS. 7A, 7B, 7C, and 7D, Table 2). Growth was evaluated in “low” (10 g/L) and “high” (20 g/L for pCA and 30 g/L for FA) substrate concentrations corresponding to the starting and late substrate levels, respectively, in the evolution experiment (FIGS. 2A through 2I, FIG. 3B). Growth rate was calculated to compare catabolic capacity and lag phase was calculated to evaluate substrate toxicity tolerance.

TABLE 2
Description of strains
Strain		Refer-
name	Description	ence
Wild-type	Pseudomonas putida KT2440 kindly provided by	ATCC ®
P. putida	Pablo I. Nikel	47054 ™
CJ782	Pseudomonas putida KT2440 ΔPP_3350	This
		study
MJD1	Pseudomonas putida KT2440 ΔttgB	This
		study
TALE#1	Pseudomonas putida KT2440 subjected to TALE in	This
	p-coumaric acid, replicate #1, mixed population	study
TALE#3	Pseudomonas putida KT2440 subjected to TALE in	This
	p-coumaric acid, replicate #2, mixed population	study
TALE#5	Pseudomonas putida KT2440 subjected to TALE in	This
	p-coumaric acid, replicate #3, mixed population	study
TALE#7	Pseudomonas putida KT2440 subjected to TALE in	This
	p-coumaric acid, replicate #4, mixed population	study
TALE#9	Pseudomonas putida KT2440 subjected to TALE in	This
	p-coumaric acid, replicate #5, mixed population	study
TALE#11	Pseudomonas putida KT2440 subjected to TALE in	This
	p-coumaric acid, replicate #6, mixed population	study
TALE#13	Pseudomonas putida KT2440 subjected to TALE in	This
	ferulic acid, replicate #1, mixed population	study
TALE#15	Pseudomonas putida KT2440 subjected to TALE in	This
	ferulic acid, replicate #2, mixed population	study
TALE#17	Pseudomonas putida KT2440 subjected to TALE in	This
	ferulic acid, replicate #3, mixed population	study
TALE#19	Pseudomonas putida KT2440 subjected to TALE in	This
	ferulic acid, replicate #4, mixed population	study
TALE#21	Pseudomonas putida KT2440 subjected to TALE in	This
	ferulic acid, replicate #5, mixed population	study
TALE#23	Pseudomonas putida KT2440 subjected to TALE in	This
	ferulic acid, replicate #6, mixed population	study
TALE#25	Pseudomonas putida KT2440 subjected to TALE in	This
	an equal mass mixture of p-coumaric acid and ferulic	study
	acid, replicate #1, mixed population
TALE#27	Pseudomonas putida KT2440 subjected to TALE in	This
	an equal mass mixture of p-coumaric acid and ferulic	study
	acid, replicate #2, mixed population
TALE#29	Pseudomonas putida KT2440 subjected to TALE in	This
	an equal mass mixture of p-coumaric acid and ferulic	study
	acid, replicate #3, mixed population
TALE#31	Pseudomonas putida KT2440 subjected to TALE in	This
	an equal mass mixture of p-coumaric acid and ferulic	study
	acid, replicate #4, mixed population
TALE#33	Pseudomonas putida KT2440 subjected to TALE in	This
	an equal mass mixture of p-coumaric acid and ferulic	study
	acid, replicate #5, mixed population
TALE#35	Pseudomonas putida KT2440 subjected to TALE in	This
	an equal mass mixture of p-coumaric acid and ferulic	study
	acid, replicate #6, mixed population
ALE#37	Pseudomonas putida KT2440 subjected to ALE in	This
	glucose, replicate #1, mixed population	study
ALE#38	Pseudomonas putida KT2440 subjected to ALE in	This
	glucose, replicate #2, mixed population	study
ALE#39	Pseudomonas putida KT2440 subjected to ALE in	This
	glucose, replicate #3, mixed population	study
ALE#40	Pseudomonas putida KT2440 subjected to ALE in	This
	glucose, replicate #4, mixed population	study
MJD2	TALE#25 (Pseudomonas putida KT2440 subjected	This
	to TALE in an equal mass mixture of p-coumaric	study
	acid and ferulic acid, replicate #1, mixed population)
	ΔttgB
MJD3	TALE#27 (Pseudomonas putida KT2440 subjected	This
	to TALE in an equal mass mixture of p-coumaric	study
	acid and ferulic acid, replicate #2, mixed population)
	ΔttgB
MJD4	TALE#31 (Pseudomonas putida KT2440 subjected	This
	to TALE in an equal mass mixture of p-coumaric	study
	acid and ferulic acid, replicate #4, mixed population)
	ΔttgB

Interestingly, CJ782 and each of the TALE endpoint populations have dramatically reduced lag phases compared to wild-type in 20 g/L pCA (FIG. 7B). These strains also exhibit slightly improved growth rates compared to wild-type, but again only in the high concentration of pCA (FIG. 7B). In agreement with the parameters from TALE experiments (FIG. 3C), these data indicate that evolution—and, more specifically, the deletion of PP_3350—results in improved tolerance but not an improved growth rate in high concentrations of pCA. In 30 g/L FA, however, FA-evolved TALE #23 displays improved catabolic capacity and improved tolerance compared to wild-type P. putida (FIG. 7C). The deletion of PP_3350 does not fully recapitulate the observed phenotype in TALE #23, indicating that additional mutations present in this population may underly the improve FA catabolic capacity. Growth rate is slightly but universally decreased in CJ782 and TALE populations in 10 g/L pCA+FA (5 g/L of each compound) but slightly increased in 20 g/LpCA+FA (10 g/L of each compound, (FIG. 7D). Given that growth advantages are modest in each compound at 10 g/L alone, this suggests that the adaptations are advantageous above a given threshold of total aromatic compound. In summary, PP_3350 deletion recapitulates the improved pCA tolerance but not improved FA catabolic capacity of TALE endpoint populations.

Materials and Methods:

Strains and media: P. putida KT2440 provided by Dr. Pablo I. Nikel was cultivated in modified M9 minimal media (1×M9 salts, 2 mM MgSO₄, 100 μM CaCl₂), 1× trace elements). M9 salts (10×) consisted of 68 g/L Na₂HPO₄ anhydrous, 30 g/L KH₂PO₄, 5 g/L NaCl, and 20 g/L (NH₄)₂SO₄. Trace elements (2000×) consisted of 3 g/L FeSO₄·7H₂O, 4.5 g/L ZnSO₄·7H₂O, 0.3 g/L CoCl₂·6H₂O, 0.4 g/L Na₂MoO₄·2H₂O, 4.5 g/L CaCl₂·H₂O, 0.2 g/L CuSO₄·2H₂O, 1 g/L H₃BO₃, 15 g/L EDTA, 0.1 g/L KI, and 0.7 g/L MnCl₂·4H₂O adjusted to pH 4 with HCl. pCA and FA (TCI, Belgium) stocks were prepared fresh prior to each experiment by dissolving each acid in H₂O and adjusting to pH 7 with NaOH. Carbon sources were added to the media in the specified concentration and the medium was sterilized by 0.22-μm filtration.

TALE and ALE experiments: The TALE and ALE experiments were conducted using an automated liquid handler platform as previously described (LaCroix et al., 2015; Mohamed et al., 2019, 2017). To prepare precultures, single isolates of P. putida on LB agar plates were inoculated at 1% (v/v) in test tubes with 15 mL M9 medium with 10 g/L glucose, 8 g/L pCA, 10 g/L FA, or 3 g/L pCA and 3 g/L FA in four biological replicates for the glucose ALE and six biological replicates for each aromatic TALE (Table 3). Cultures were incubated at 30° C. in a shaking heat block and OD₆₀₀ was measured continuously. Periodically, aliquots of cultures were sampled, mixed with 25% glycerol, and frozen at −80° C. for DNA sequencing. Whole genome sequencing and analysis: For each aromatic TALE (pCA, FA, and pCA+FA) and the glucose ALE, 1-2 intermediate isolates, the endpoint population, and a single endpoint isolate were selected and prepared for whole genome sequencing as follows. Isolates were chosen from agar plates with M9 media and the corresponding carbon source, inoculated into LB medium and cultivated overnight, genomic DNA was extracted with PureLink® Genomic DNA Extraction kit (Invitrogen, Calif., USA), quality was assessed by evaluating Abs_{260 nm}/Abs_{280 nm} using a NanoDrop, DNA concentration was measured using a Qubit assay, and paired-end resequencing libraries were generated using the Illumina 300 cycle (150 bp×2) kit (San Diego, Calif., USA). Sequencing was performed on an Illumina NextSeq XX system (Illumina, USA). The sequencing files were analyzed using a previously described in-house script (Phaneuf et al., 2019) based on bowties2 and Breseq (version 0.30.1) and the NCBI NC 002947 reference genome for P. putida KT2440 was used for annotation of genes. For population samples, a filter was applied to exclude mutations with a frequency of less than 0.50, unless the same mutation was found in an isolate. Converged mutations were identified by comparing all clonal and population samples and selecting genes or genetic regions which presented a mutation in >2 independent TALE or ALE experiments, either replicates on the same carbon source or in a different carbon source.

TABLE 3
TALE and ALE experimental conditions. Six independent and parallel replicates
were performed for the p-Coumaric acid (pCA) TALE, ferulic acid (FA) TALE, and equimolar
pCA and FA TALE. Four independent and parallel replicates were performed for the glucose ALE.
					Final
			Initial		growth	Fold-
			growth		rate with	change	Total
			rate with	Average	ending	in	number of	Cumulative
		Starting	starting	ending	conc.	carbon	flasks	cell division	No. of cell
Condition	ALE #	conc. (g/L)	conc. (h−1)	conc. (g/L)	(h−1)*	source	passaged	(CCD), ×1012	generations
pCA	1	8	0.12 ± 0.01	25.6	0.08	3.20	62	2.15	311
TALE	3			27.2	0.17	3.40	69	2.28	347.5
	5			25.6	0.09	3.20	73	2.47	369.5
	7			27.2	0.08	3.40	70	2.35	352.6
	9			27.2	0.09	3.40	76	2.43	381.2
	11			25.6	0.12	3.20	66	2.18	336
	AVG			26.40	0.11	3.30	69.33	2.31	349.63
	STDEV			0.88	0.04	0.11	4.97	0.13	24.83
FA	13	10	0.13 ± 0.01	40	0.26	4.00	104	3.09	574.3
TALE	15			40	0.29	4.00	115	3.49	622.5
	17			40	0.34	4.00	108	3.42	594.8
	19			40	0.34	4.00	120	3.39	658.4
	21			40	0.34	4.00	114	3.33	622.8
	23			40	0.31	4.00	115	3.49	632.5
	AVG			40.00	0.31	4.00	112.67	3.37	617.55
	STDEV			0.00	0.03	0.00	5.72	0.15	29.44
pCA + FA	25	6	0.18 ± 0.01	20.4	0.12	3.40	98	3.42	602.4
TALE	27			20.4	0.11	3.40	104	3.63	538.6
	29			20.4	0.08	3.40	104	3.44	535
	31			20.4	0.12	3.40	103	3.51	531.5
	33			17.5	0.18	2.92	109	3.69	558.7
	35			19.8	0.18	3.30	97	3.16	493.3
	AVG			19.82	0.13	3.30	102.50	3.48	543.25
	STDEV			1.16	0.04	0.19	4.42	0.19	35.94
Glucose	37	10	0.50 ± 0.01	10	0.83	0	141	6.36	917.8
ALE	38	(constant)		(constant)	0.85		143	6.53	934.9
	39				0.87		141	6.37	919.5
	40				0.83		140	6.43	913.5
	AVG				0.85		141.25	6.42	921.43
	STDEV				0.02		1.26	0.08	9.33

Evaluation of TALE endpoint populations: Cells were revived from glycerol stocks on M9 minimal media plates supplemented with 5 g/L of the carbon compound(s) from which the populations were evolved, inoculated into 15 mL of M9 minimal medium containing 5 g/L of the same aromatic compound used in the plates, and incubated at 30° C., 1100 rpm until the OD₆₀₀ reached 3.0. Cells were inoculated into fresh M9 minimal medium supplemented with the carbon source specified in each experiment at a 1:100 dilution in test tubes with biological duplicates and incubated at 30° C. with aeration provided by a magnetic stir bar. OD₆₀₀ was measured using the Sunrise plate reader (Tecan Group Ltd., Switzerland).

Plasmids and strain construction: Deletion of PP_3350 was performed using the antibiotic/sacB method of gene replacement, as described previously. The plasmid pCJ222 for deleting PP_3350 was constructed by amplifying an PP_3350 homology regions by PCR from P. putida genomic DNA (Table 4, Table 5), assembly into the pK18sB plasmid digested with EcoRI and HindIII using NEBuilder® HiFi DNA Assembly Master Mix (New England Biolabs, USA), transformation into NEB E. coli DH5-alpha F′Iq cells, and the correct sequence was verified using Sanger sequencing (GENEWIZ, Germany). pCJ222 was transformed into P. putida as previously described and sucrose selection and diagnostic colony PCR were followed to identify a clone with proper deletion mutation. The resulting strain was named CJ782 (Table 2). When needed, antibiotics were used at the following concentrations: 30 μg/mL chloramphenicol, 50 μg/mL kanamycin, or 10 μg/mL gentamicin.

Evaluation of reverse-engineered P. putida ΔPP_3350 and endpoint TALE populations: Cells were revived from glycerol stocks in 50 mL M9 minimal medium supplemented with 3 g/L of the aromatic compound from which the populations were evolved or 10 g/L glucose in baffled flasks and incubated at 30° C. and 225 rpm until the OD₆₀₀ reached 3.0. Cells were inoculated in fresh medium to an OD₆₀₀ in 300 μL and incubated in 100-well honeycomb plates in a BioscreenC™ (Growth Curves USA, USA) at 30° C., maximum continuous shaking, and Abs_420-580 measurements were taken every 15 minutes.

TABLE 4
Primers
Primer name	Primer sequence, 5’ → 3’	Purpose
oCJ680 (SEQ ID	TTTGTGATGCTCGTCAGGG	Sequencing a pK18sB insert
NO: 3)
oCJ681 (SEQ ID	CTTCCCAACCTTACCAGAG	Sequencing a pK18sB insert
NO: 4)
oCJ791 (SEQ ID	ACATGATTACGAATTCCGGACATCAGCATCGC	Amplifying the upstream
NO: 5)		targeting region for PP_3350
oCJ792 (SEQ ID	TTAAACACTTGTTTTTATAATTGTTCTTACAAACTGG
NO: 6
oCJ793 (SEQ ID	TTATAAAAACAAGTGTTTAAACCCACCCGACCGATAACAAC	Amplifying the downstream
NO: 7)		targeting region for PP_3350
oCJ794 (SEQ ID	TGCCAAGCTTTCAGCGACGCAACCGC
NO: 8)
oCJ795 (SEQ ID	GTCTCCGACATCATGCCCAGC	Confirming deletion of PP_3350
NO: 9)		by colony PCR
oCJ796 (SEQ ID	GTAGAACACCGTACGCCAACCG
NO: 10)
TEAM-1640	ACCCACCGCCCTGGTGGTCAACC	Confirming deletion of PP_1385
(SEQ ID NO: 11)		(ttgB) by colony
TEAM-1641	CAGGGATCAGCGAGCAGCCGCCAAG	PCR (outside-outside pair)
(SEQ ID NO: 12)
F-5'ttgAend	CGTCGAGGTGAAGGTCAGCGATGC	Confirming deletion of ttgB in
(SEQ ID NO: 13)		TALE knockouts
RttgCbeg	CCGATTGCGTCGGCGAGATAAGCAG
(SEQ ID NO: 14)

TABLE 5
Plasmids
Plasmid name	Purpose	Reference
pK18mobsacB	Non-replicative kanR sacS; allelic	GenBank:
	exchange plasmid in P. putida KT2440	MH166772
pCJ222	Deletion of PP_3350 from the	This study
	chromosome of P. putida KT2440
pK18mosacB	Non-replicative kanR sacS; allelic	(Schäfer et al.
	exchange plasmid in P. putida KT2440	1994)
pTE289	For the deletion of ttgB (ΔPP_1385)	This study
	from the chromosome of
	P. putida KT2440

The foregoing discussion and examples have been presented for purposes of illustration and description. The foregoing is not intended to limit the aspects, embodiments, or configurations to the form or forms disclosed herein. In the foregoing Detailed Description for example, various features of the aspects, embodiments, or configurations are grouped together in one or more embodiments, configurations, or aspects for the purpose of streamlining the disclosure. The features of the aspects, embodiments, or configurations, may be combined in alternate aspects, embodiments, or configurations other than those discussed above. This method of disclosure is not to be interpreted as reflecting an intention that the aspects, embodiments, or configurations require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment, configuration, or aspect. While certain aspects of conventional technology have been discussed to facilitate disclosure of some embodiments of the present invention, the Applicants in no way disclaim these technical aspects, and it is contemplated that the claimed invention may encompass one or more of the conventional technical aspects discussed herein. Thus, the following claims are hereby incorporated into this Detailed Description, with each claim standing on its own as a separate aspect, embodiment, or configuration.

Claims

1. A genetically modified Pseudomonas comprising: a mutation of a gene encoding a cell membrane protein wherein:the mutation improves tolerance to a hydroxycinnamic acid, andthe gene encodes for a protein that is at least 92% identical to SEQ ID NO: 2.

2. The genetically modified Pseudomonas of claim 1 capable of converting hydroxycinnamic acid to muconate.

3. The genetically modified Pseudomonas of claim 1 wherein the mutation of a gene encoding a cell membrane protein decreases the time that the Pseudomonas spends in a lag phase when exposed to a solution of hydroxycinnamic acid compared to a non-genetically modified Pseudomonas.

4. The genetically modified Pseudomonas of claim 1 wherein the mutation increases a growth rate of the Pseudomonas when exposed to a solution of hydroxycinnamic acid compared to a non-genetically modified Pseudomonas.

5. The genetically modified Pseudomonas of claim 1, wherein the gene is at least 92% identical to SEQ ID NO: 1.

6. The genetically modified Pseudomonas of claim 1, wherein the hydroxycinnamic acid is selected from the group consisting of coumarate and ferulate.

7. The genetically modified Pseudomonas of claim 1, wherein the Pseudomonas is P. putida K2440.

8. The genetically modified Pseudomonas of claim 1, wherein the Pseudomonas demonstrates at least a 3.3-fold increased tolerance to p-coumaric acid (pCA) compared to a non-genetically modified Pseudomonas.

9. The genetically modified Pseudomonas of claim 1, wherein the Pseudomonas has at least a 37 hour decrease in lag phase when exposed to 20 g/L pCA compared to a non-genetically modified Pseudomonas.

10. The genetically modified Pseudomonas of claim 1, wherein the Pseudomonas has at least a 2.4-fold increased growth rate when exposed to 20 g/L pCA compared to a non-genetically modified Pseudomonas.

11. A method for lignin valorization, the method comprising: converting a hydroxycinnamic acid to muconate by contacting the hydroxycinnamic acid with a genetically modified Pseudomonas, wherein:the Pseudomonas comprises a mutation of a gene encoding a cell membrane protein,the modification increases the uptake of the hydroxycinnamic acid compared to a non-genetically modified Pseudomonas, andthe gene encodes for a protein that is at least 92% identical to SEQ ID NO: 2.

12. The method of claim 11 wherein the mutation decreases the time in a lag phase of the Pseudomonas when the Pseudomonas is exposed to a solution of hydroxycinnamic acid compared to a non-genetically modified Pseudomonas.

13. The method of claim 11 wherein the mutation increases a growth rate of the Pseudomonas when exposed to a solution of hydroxycinnamic acid compared to a non-genetically modified Pseudomonas.

14. The method of claim 11 wherein the mutation is to a gene that is at least 92% identical to SEQ ID NO: 1.

15. The method of claim 11 wherein the hydroxycinnamic acid is selected from the group consisting of coumarate, and ferulate.

16. The method of claim 11 wherein the Pseudomonas has at least a 3.3-fold increased tolerance to pCA, at least a 37 hour decrease in lag phase, and a 2.4-fold increased growth rate when exposed to 20 g/L pCA compared to a non-genetically modified Pseudomonas.

17. A genetically modified Pseudomonas comprising: a deletion of a gene encoding a cell membrane protein, wherein:the deletion improves tolerance to a hydroxycinnamic acid, andthe deleted gene encodes for the expression of protein PP_3350.

18. A method for lignin valorization, the method comprising: converting a hydroxycinnamic acid to muconate by contacting the hydroxycinnamic acid with a genetically modified Pseudomonas, wherein:the Pseudomonas comprises a deletion of a gene encoding a cell membrane protein,the modification increases the uptake of the hydroxycinnamic acid compared to a non-genetically modified Pseudomonas, andthe deleted gene encodes for the expression of protein PP_3350.